Chargement en cours...

Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis

A recent clinical trial using the 9-valent human papillomavirus virus (HPV) vaccine has shown that antibody responses after 2 doses are noninferior to those after 3 doses, suggesting that 2 and 3 doses may have comparable vaccine efficacy. We used an individual-based transmission-dynamic model to co...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Infect Dis
Auteurs principaux: Laprise, Jean-François, Markowitz, Lauri E., Chesson, Harrell W., Drolet, Mélanie, Brisson, Marc
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2016
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4978371/
https://ncbi.nlm.nih.gov/pubmed/27234416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiw227
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!